Sobrera Pharma, and Recipharm have entered into an agreement for the formulation development and manufacturing of SO-001, a new oral treatment for Alcohol Use Disorder (AUD). A phase II study is underway to test the efficacy and safety of the new therapy, which acts through dopamine, which plays an important role in the reward system. Preclinical and clinical data support the development of this new product to be developed at Recipharm’s Centre of Excellence in Oral Solids. Bernard Pluta...